Five talks on offer.
- 01
The 351 vs 361 Decision That Kills Most Exosome Programs
For biotech founders, regulatory counsel, and capital allocators. Why most cell-derived therapeutic programs land on the wrong side of FDA jurisdiction. CMC, manufacturing controls, and the cost of misclassification. 45 minutes plus Q&A.
- 02
Family Office Capital for FDA-Regulated Science
For LPs, family office principals, biotech operators. Why patient capital fits regulated biotech better than venture timelines. Structuring investment milestones to FDA decision points rather than fundraising rounds.
- 03
Compliance Failures That Precede Enforcement
For healthcare operators, in-house counsel, and CFOs. Documentation patterns and operating signals that show up before federal action. HIPAA, AKS, Stark, OIG, and what thirty years inside FDA-regulated ventures has taught.
- 04
Targeted Osmotic Lysis: Mechanism and Regulatory Pathway
For oncology audiences, clinicians, and biotech investors. The mechanism behind TOL, the
an academic medical foundation partnership, and the regulatory pathway it would have to clear.
- 05
Building Frontier Biotech From Dallas
For Dallas civic, university, and ecosystem audiences. The Dallas biotech network, Methodist, UT Southwestern, and why this is the place to build regulated healthcare today.
Booking terms.
Keynotes & panels
Available for keynote talks, panel participation, and fireside conversation formats. Strong fit for biotech, regulatory, and family office events.
University guest lectures
Available for university guest lectures, particularly at UT Arlington, UT Dallas, and Texas A&M Health Science Center. No fee for student-facing engagements.
Podcasts & long-form interviews
Open to long-form podcast and interview formats. No publicist filter, direct response. Preference for shows that go past the surface.
Press & expert commentary
Available for press commentary on FDA biologics policy, exosome regulatory science, frontier oncology, and healthcare compliance. Quotes attributed and verified.